[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Clinical trials

Inebilizumab shows promise for IgG4-RD

Nature Reviews Rheumatology (2024)Cite this article

Subjects

Access through your institution
Buy or subscribe

Results from the phase III MITIGATE trial demonstrate the efficacy of CD19-targeted B cell depletion with inebilizumab for the treatment of IgG4-related disease (IgG4-RD), a condition for which there are currently no approved pharmacotherapies.

In the parallel-cohort, double-blind trial, conducted at 80 sites across 22 countries, 135 adults with active IgG4-RD were randomly assigned to receive treatment with inebilizumab or placebo; for all participants, glucocorticoid treatment was tapered over 8 weeks.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Related article

  • Perugino, C. A. & Stone, J. H. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat. Rev. Rheumatol. 16, 702–714 (2020)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Rheumatology http://www.nature.com/nrrheum/

    Sarah Onuora

Authors
  1. Sarah Onuora
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Onuora.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Onuora, S. Inebilizumab shows promise for IgG4-RD. Nat Rev Rheumatol (2024). https://doi.org/10.1038/s41584-024-01206-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41584-024-01206-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing